Lotus Pharmaceutical Announces Commencement of Uro-Vaxom® Distribution in South Korea

Taipei, Taiwan, and Seoul, South Korea, 7 July 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, today announced that its wholly owned subsidiary Alvogen Korea has commenced distribution of Uro-Vaxom® in South Korea, as part of the commercial transition under Lotus’ previously announced agreement with OM Pharma1 to acquire the product rights in South Korea. OM Pharma is a global biopharmaceutical company headquartered in Geneva, Switzerland.

As part of the commercial transition arrangements under the agreement, Alvogen Korea assumed responsibility for the distribution of Uro-Vaxom® effective 1 July 2026. The transfer of the marketing authorisation to Alvogen Korea is expected to be completed in the fourth quarter of 2026.

Uro-Vaxom® has an established clinical profile and long-standing market presence as an oral immunoactive product for the prevention of recurrent urinary tract infections. The product is currently marketed in more than 40 countries and reached more than one million patients globally in 2025. The addition of Uro-Vaxom® adds to Lotus' specialty portfolio in urology and infectious disease prevention, further strengthening the Company's commercial presence in South Korea, one of its key Asian markets.

Petar Vazharov, Chief Executive Officer of Lotus, commented, “The rapid commencement of Uro-Vaxom® distribution demonstrates our ability to execute efficiently, enabling a smooth commercial transition for the product. As Alvogen Korea assumes distribution responsibility, our priority is to maintain a reliable supply of Uro-Vaxom® and support continuity of care for patients. The addition of Uro-Vaxom® will further strengthen our urology portfolio in South Korea, and we remain committed to expanding our presence in differentiated branded medicines across Asia.”

Uro-Vaxom® is a registered trademark. All other trademarks are the property of their respective owners.

1 https://www.lotuspharm.com/en/newsroom/news-page/323

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness.

OM Pharma transforms immune health with bacterial lysates-innovative therapies that train and strengthen the body’s natural defenses. By prioritizing prevention, the company helps reduce infections and protect vulnerable populations. Headquartered in Geneva, where its biotech site is also based, OM Pharma’s products are available in 100 countries and reach 16 million people globally through a trusted network of partners and affiliates. www.ompharma.com